User:Mr. Ibrahem/Ruxolitinib

Ruxolitinib, sold under the brand names Jakafi and Jakavi, is a medication used to treat myelofibrosis, polycythemia vera (PCV), and graft-versus-host disease (GvHD). It is used in PCV when hydroxyurea is not sufficient and in GvHD that is unresponsive to other measures. It is taken by mouth.

Common side effects include low platelets, low red blood cells, low neutrophils, bleeding, liver problems, and abnormal lipids. Other side effects may include infection, skin cancer, blood clots, and heart disease. Use in pregnancy may harm the baby. It is a kinase inhibitor.

Ruxolitinib was approved for medical use in the United States in 2011 and Europe in 2012. In the United States it costs about 15,800 USD per month as of 2021. In the United Kingdom this amount costs the NHS about £3,000.